The Science of Saying Yes

Three letters — PBM — have become the villain of every drug-pricing story. A cardiologist who crossed over to work inside one makes the affirmative case: that this is, at its best, the science of good, efficient, evidence-based care, practiced at the scale of a population.

It happens like clockwork. I'm in easy conversation with a fellow physician, the shop talk flowing, and then they ask what I do now. I tell them: I work for a pharmacy benefit manager. The three letters land, and I watch the warmth go out of the room — that small, almost involuntary tightening that says I've just confessed to working for the other side. I've seen the look more times than I can count. I've also learned to wait, because remarkably often it's followed by a second expression, and a question I'll come back to.

I came to it the long way. I trained as a pharmacist before I trained as a physician, spent a career in cardiology, and only later crossed into managed care. I expected to find spreadsheets. I found medicine — practiced not one patient at a time, but a million at once. That turns out to be a harder and more consequential kind of practice than I appreciated from the bedside, and a good deal humbler, because at this scale both your mistakes and your mercies multiply.

The caricature says the pharmacy benefit manager is the department of no. The truth is closer to the opposite. The real work is the science of yes — deciding, out of the thousands of products a pharmaceutical industry would happily sell us, which ones actually deserve a place in a patient's hands, and then making sure those reach them reliably, affordably, and safely. Saying yes to the right thing is far harder than saying no to everything.

Consider the formulary — the list of covered drugs that outsiders picture as a price sheet. It is not a price sheet. It is a clinical document. Behind each line sits a pharmacist and a physician asking the questions a good doctor always asks: Does this work better than what we already have? Is it safer? Is the evidence real, or is it a glossy brochure dressed up as a trial? When two drugs do the same job and one costs ten times more for no added benefit, choosing the first is not rationing. It is judgment — the same judgment I was trained to exercise at the bedside, only now the bedside is the size of a state.

Efficiency, I've come to believe, is a moral act and not merely a financial one. Every system of care draws from a finite well; the dollar spent on a me-too drug that helps no one more than its generic twin is a dollar that cannot reach the insulin, the inhaler, the cancer therapy a patient three counties over can't afford. I think about it the way I think about my other obsession, the night sky. An observatory has only so many clear, dark hours in a year. You cannot photograph everything, so you choose the targets where the light will matter most — and that discipline is not a denial of wonder. It is the only way to come home with a real image instead of a blurred one.

Stewardship is not the enemy of generosity. It is how generosity is made to last.

And then there is the phrase I'd defend above the rest: scientifically based. Medicine is forever tempted by the anecdote, the sales call, the newest thing simply because it is new. A well-run benefit is a quiet bulwark against all of it — insisting on evidence over marketing, catching the dangerous interaction the hurried clinic missed, flagging the duplicated therapy, steering the system toward the generics and biosimilars that are among the great unsung triumphs of modern pharmacology. Most of this work is invisible. No patient ever feels the harm that didn't befall them. But it didn't befall them because someone, somewhere, was paying scientific attention.

And make no mistake about the people doing this work. It is no soft landing for physicians who tired of medicine — it is one of the most scrutinized seats I have ever occupied. We answer at once to the company, to its clients, to its vendors, to the prescribers whose decisions we review, and — always, finally — to patients. We keep our state licenses current, our board certifications active, our continuing education unrelenting, because the moment our knowledge slips, so does our judgment, and judgment is the whole of the job. The standards are exacting and the accountability runs in every direction. The weak don't last here; the strong sharpen. You do not earn the right to weigh in on another physician's prescription unless you have stayed, demonstrably, at the top of your own game.

None of this means the field has earned the right to stop listening. The suspicion is not baseless; trust in any institution that stands between a patient and their medicine has to be earned continuously, in daylight, through transparency and plain dealing. I hold no brief for opacity. But the answer to an imperfect steward is a better steward — not the fantasy that no one has to choose. Someone will always have to decide what good and finite resources should buy. I would rather that someone be a clinician, armed with evidence and accountable for the outcome, than a marketing department.

And now the question I promised you. More than once — more than twice — the very colleague whose face soured at the acronym has, a few minutes later and in a notably lower voice, asked me how a person might get a job like mine. I've come to treasure that moment, because it says what the first look was too proud to. The disdain is the fashion; the curiosity is the tell. Somewhere beneath the reflex, a good doctor senses what the caricature conceals — that this is real medicine, done at a scale that can actually move the needle, and that the problems here are the interesting kind: hard, consequential, worth a careful mind. They don't want in because the work is easy to mock. They want in because, once you look, it is easy to respect.

So I wait out the first look, and I tell the truth as I've found it. The work is not the villain of the story. On its best days it is medicine at its most ambitious — the attempt to make care good where it could be careless, efficient where it could be wasteful, and scientifically sound where it could be swayed. I spent the first half of my career trying to do that one patient at a time. I am spending the second half trying to do it for everyone at once. Both, it turns out, are the same oath.